Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Lipoglycopeptide
| Lipoglycopeptide | |
|---|---|
| Drug class | |
 | |
| Class identifiers | |
| Use | Antibiotic |
| ATC code | J01XA |
| Mode of action | Bacterial cell wall disruption |
| Mechanism of action | Inhibit peptidoglycan glycosyltransferase chain elongation |
| Legal status | |
| In Wikidata | |
Lipoglycopeptides are a class of antibiotic that have lipophilic side-chains linked to glycopeptides. The class includes oritavancin, telavancin and dalbavancin.[1][2]
In September 2009 the US Food and Drug Administration (FDA) approved telavancin (Vibativ) for complicated skin and skin structure infections (cSSSI) On May 23, 2014, the FDA approved dalbavancin (Dalvance), an injectable drug, administered intravenously in two doses one week apart. On August 6, 2014, the FDA approved oritavancin (Orbactiv), an injectable drug administered as a single dose to comprise a full course of therapy.
Telavancin is the most potent of the three against Clostridium spp.[3]
- ^ Kahne, Dan; Leimkuhler, Catherine; Lu, Wei; Walsh, Christopher (2005). "Glycopeptide and Lipoglycopeptide Antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
- ^ "Fight Against Antimicrobial Resistance Recruiting New Agents". 1 Feb 2011.
- ^ Zhanel, George G.; Calic, Divna; Schweizer, Frank; Zelenitsky, Sheryl; Adam, Heather; Lagacé-Wiens, Philippe R.S.; Rubinstein, Ethan; Gin, Alfred S.; et al. (2010-05-07). "New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin". Drugs. 70 (7): 859–886. doi:10.2165/11534440-000000000-00000. PMID 20426497. S2CID 207298905.
Previous Page Next Page
